Last update Jan. 19, 2021
Derived from long-acting benzodiazepines with properties similar to diazepam. Indicated in the short-term treatment of anxiety disorders.
Oral administration once or twice a day.
It is excreted in human milk in a small amount, but it could be clinically significant: RD 6 -12% (Nishimura 2021).
No problems have been observed in infants whose mothers have taken it (Nishimura 2021).
It has very few bibliographical references and is marketed in few countries.
Until there is more published data on this drug in relation to breastfeeding, safer known alternatives are preferable.
It is advisable to choose short-acting benzodiazepines and use the minimum effective dose (Rowe 2013), especially during the neonatal period and in cases of prematurity because they can accumulate in the infant during chronic use (Sachs 2013).
It is advisable to monitor drowsiness and the adequate feeding of the infant.
It is not recommended to share a bed with the baby if this medication is being taken due to an increased risk of suffocation or sudden infant death (UNICEF 2018, 2017, 2014 and 2013, Landa 2012, ABM 2008, UNICEF 2006).
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2006 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM